nach oben

Erschienen in:

03.09.2020 | Supportivtherapie

Misteltherapie in der Onkologie

Komplementärmedizin für eine bessere Lebensqualität

verfasst von: Dr. med. Daniela Paepke

Erschienen in: Im Fokus Onkologie | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Auszug

Eine große Anzahl onkologischer Patienten erhält im Verlauf ihrer Erkrankung eine Misteltherapie. Sie gehört in Deutschland zu den am meist verordneten komplementärmedizinischen Krebsmedikamenten. Eine Vielzahl präklinischer Forschungen, klinischer Studien und Übersichtsarbeiten liegen zur Misteltherapie vor. Hautsächlich findet sie Anwendung zur Verbesserung der Lebensqualität und zur Verminderung systemtherapeutisch bedingter Nebenwirkungen. Neuere Studienergebnisse zeigen neben einer Verbesserung der Lebensqualität auch einen Überlebensvorteil durch den Einsatz der Mistel. …

Anonymus. Ein neues Krebsheilmittel. Cancerodoron. Neues Wiener Journal. 1924

Wilkens J, Scheffler A. Misteltherapie: differenzierte Anwendung der Mistel nach Wirtsbäumen: Georg Thieme Verlag; 2006.

Bopp A. Die Mistel - Heilpflanze in der Krebstherapie. Zürich: Rüffer & Rub Sachbuchverlag; 2006.

Wilkens J. Misteltherapie. Differenzierte Anwendung der Mistel nach Wirtsbäumen. Stuttgart: Sonntag-Verlag; 2006.

Stettin A et al. Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from VISCUM ALBUM L. and neutralize lectin- induced cytotoxicity in vitro. Klinische Wochenschrift. 1990;68:896-900

Beuth J et al. Intratumoral application of standardized mistletoe extracts downregulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model. Anticancer Research. 2006;26(6B): 4451-6

Büssing A. Induction of apoptosis by the mistletoe lectins: A review on the mechanisms of cytotoxicity mediated by VISCUM ALBUM L. Apoptosis. 1996;1:25-32

Janssen O, Scheffler A, Kabelitz D. In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung. 1993;43(11):1221-7

Twardziok M et al. Multiple Active Compounds from Viscum album L. Synergistically Converge to Promote Apoptosis in Ewing Sarcoma. PLoS One. 2016;11(9):e0159749

10.

Elluru SR et al. Antiangiogenic properties of VISCUM ALBUM extracts are associated with endothelial cytotoxicity. Anticancer Res. 2009;29(8):2945-50

11.

Kienle GS, Kiene H. Die Mistel in der Onkologie: Fakten und konzeptionelle Grundlagen. Stuttgart:Schattauer Verlag; 2003

12.

Franz H et al. The toxic A-chain of mistletoe lectin I: Isolation and its effect on cell-free protein synthesis. Acta biologica et medica Germanica. 1982;41(4):K9-K16

13.

Metzner G et al. Effects of lectin I from mistletoe (ML I) and its isolated A and B chains on human mononuclear cells: mitogenic activity and lymphokine release. Pharmazie. 1987;42(5):337-40

14.

Marvibaigi M et al. Jaganathan SK. Preclinical and clinical effects of mistletoe against breast cancer. BioMed Research International: Hindawi Publishing Corporation; 2014

15.

Schaller G, Urech K, Giannattasio M. Cytotoxicity of different viscotoxins and extracts from the European subspecies of VISCUM ALBUM L. Phytotherapy Res. 1996;10(6):473-7

16.

Büssing A. Mistletoe. The Genus Viscum. Amsterdam, the Netherlands: Hardwood Academic Publishers; 2000

17.

Hoffmann F. Versorgung mit Krebstherapeutika im Jahr 2010. Glaeske G, Schicktanz C. Schriftreihe zur Gesundheitsanalyse. Schwäbisch Gmünd: Barmer GEK; 2011

18.

Weis J et al. Complementary medicine in cancer patients: Demand, patients' attitudes and psychological beliefs. Onkologie. 1998;21:144-9

19.

Fasching PA et al. Association of complementary methods with quality of life and life satisfaction in patients with gynecologic and breast malignancies. Support Care Cancer. 2007;15(11):1277-84

20.

Drozdoff L et al. Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy. BMC Complement Altern Med. 2018;18(1):259

21.

Horneber MA et al. Mistletoe therapy in oncology. Cochrane Database Syst Rev. 2008;2008(2):CD003297

22.

Kienle GS et al. Mistletoe in cancer - A systematic review on controlled clinical trials. Eur J Med Res. 2003;8(3):109-19

23.

Kienle GS et al. Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res. 2009;28(1):79

24.

Melzer J et al. Efficacy and safety of mistletoe preparations (VISCUM ALBUM) for patients with cancer diseases. Forsch Komplementärmed. 2009;16(4):217-26

25.

Büssing A, Raak C, Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Alternat Med. 2012;2012(2):219402

26.

Ostermann T, Bussing A. Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis. Explore (NY). 2012;8(5):277-81

27.

Kienle GS et al. The subjective dimension of integrative cancer care: a qualitative study exploring the perspectives, themes, and observations of experienced doctors from the area of anthroposophic medicine. Explore (NY). 2018;14(5):342-51

28.

Zänker KS, Kaveri SV. Mistletoe: From Mythology to Evidence-Based Medicine. Transl Res Biomed. Basel, Karger; 2015

29.

Tröger W et al. Lebensqualität von Patienten mit fortgeschrittenem Pankreaskarzinom unter Misteltherapie. Eine randomisierte kontrollierte Studie. Dtsch Ärztebl Int. 2014;111:493-502

30.

Kienle GS, Kiene H. Influence of VSICUM ALBUM L (European Mistletoe) extracts on quality of life in cancer patients: A systematic review of controlled clinical studies. Integr Cancer Ther. 2010;9(2):142-57

31.

Bar-Sela G et al. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer. 2013;49(5):1058-64

32.

Bock PR et al. Efficacy and safety of long-term complementary treatment with standardised European mistletoe extract (VISCUM ALBUM L.) in addition to the conventional adjuvant oncological therapy in patients with primary non-metastatic breast cancer. Arzneimittelforschung. 2004;54(8):456-66

33.

Pelzer F, Tröger W. Complementary treatment with mistletoe extracts during chemotherapy: safety, neutropenia, fever, and quality of life assessed in a randomized study. J Altern Complement Med. 2018;24(9-10):954-61

34.

Lyman GH et al. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. J Clin Oncol. 2018;36(25):2647-55

35.

Greenlee H et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017;67(3):194-232

36.

Savoie A et al. Activation of human neutrophils by the plant lectin VISCUM ALBUM agglutinin-I: modulation of de novo protein synthesis and evidence that caspases are involved in induction of apoptosis. J Leukoc Biol. 2000;68(6):845-53

37.

Weber K et al. Stimulation of neutropoiesis by a special standardized mistletoe preparation after cyclophosphamide chemotherapy in mice. Arzneimittelforschung. 1996;46(12):1174-8

38.

Pelzer F et al. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study. J Altern Complement Med. 2018;24(9-10):954-6

39.

Nazaruk J, Orlikowski P. Phytochemical profile and therapeutic potential of Viscum album L. Nat Prod Res. 2016;30(4):373-85

40.

Oei SL et al. Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies. Evid Based Complement Alternat Med. 2019;2019:5893017

41.

Büssing A et al. Keine Stimulation in vitro kultivierter Tumorzellen durch Mistellektin. Deutsche Zeitschrift für Onkologie. 2004;36(2):66-70

42.

Mansky PJ et al. NCCAM/NCI Phase 1 study of mistletoe extract and Gemcitabine in patients with advanced solid tumors. Evid Based Complement Alternat Med. 2013;2013:964592

43.

Weissenstein U et al. Interaction of standardized mistletoe (VISCUM ALBUM) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complement Altern Med. 2014;14:6

44.

Hong CE, Park AK, Lyu SY. Synergistic anticancer effects of lectin and doxorubicin in breast cancer cells. Mol Cell Biochem. 2014;394(1-2):225-35

45.

Beuth J et al. Tumorwachstumsstimulation durch Mistelpräparate? Fakten und Artefakte. Deutsche Zeitschrift für Onkologie. 2008;40(1):12-9

46.

Burger AM et al. No evidence of stimulation of human tumor cell proliferation by a standardized aqueous mistletoe extract in vitro. Anticancer Res. 2003;23(5A):3801-6

47.

Schink M, Dehus O. Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities. BMC Complement Altern Med. 2017;17(1):521

48.

Weissenstein U et al. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro. BMC Complemen Altern Med. 2019;19(1):23

49.

Burkhart J et al. In vitro investigation into the potential of a mistletoe extract to alleviate adverse effects of cyclophosphamide. Altern Ther Health Med. 2010;16(3):40-8

50.

Weissenstein U et al. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro. BMC Complement Altern Med. 2016;16:271

51.

Matthes H et al. Molecular mistletoe therapy: Friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Curr Mol Med. 2010;10(4):430-9

52.

Axtner J et al. Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer. BMC Cancer. 2016;16:579

53.

Thronicke A et al. Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. BMC Complement Altern Med. 2017;17(1):534

54.

Bar-Sela G. White-Berry Mistletoe (Viscum album L.) as complementary treatment in cancer: Does it help? Eur J Integr Med. 2011;3:e55-e62

55.

Steele ML et al. Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients. Evid Based Complement Alternat Med. 2014;2014:724258

56.

Ostermann T, Raak C, Büssing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer. 2009;9:451

57.

Tröger W et al. Viscum album L. extract therapy in patients with locally advanced or metastatic pancreatic cancer: A randomised clinical trial on overall survival. Eur J Cancer. 2013;49(18):3788-97

58.

Schad F et al. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One. 2018;13(8): e0203058

59.

Ostermann T et al. Systematic Review and Meta-Analysis on the Survival of Cancer Patients Treated with a Fermented Viscum album L. Extract (Iscador): An Update of Findings. Complement Med Res. 2020; https://doi.org/10.1159/000505202

Titel: Misteltherapie in der Onkologie
Komplementärmedizin für eine bessere Lebensqualität
verfasst von: Dr. med. Daniela Paepke
Publikationsdatum: 03.09.2020
Verlag: Springer Medizin
Erschienen in: Im Fokus Onkologie / Ausgabe 4/2020
Print ISSN: 1435-7402
Elektronische ISSN: 2192-5674
DOI: https://doi.org/10.1007/s15015-020-2424-0

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Komplementärmedizin für eine bessere Lebensqualität

Auszug

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Vitrakvi®- erster Wirkstoff mit tumoragnostischer Indikation bei NTRK-Fusions-positiven Tumoren

Auch bei Brustkrebs: Schwerer COVID-19-Verlauf selten

Morbus Waldenström: Neuer BTK-Inhibitor besser verträglich?

++ Ticker ++ ASCO 2020 ++ Ticker ++ ASCO 2020 ++ Ticker ++ ASCO 2020 ++ Ticker ++ ASCO 2020 ++

Pflege bei akuter Leukämie: Auf Befind-lichkeit und Symptome fokussieren

Patienten sind kurz nach Krebstherapie besonders durch COVID-19 gefährdet

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie